新型抗抑郁药伏硫西汀个体化用药研究进展  

Progress in Individualized Medication of Novel Antidepressant Vortioxetine

作　　者：戴丽静 杨烨 陈玉清[1] 温预关[1] DAI Lijing;YANG Ye;CHEN Yuqing;WEN Yuguan(PhaseⅠClinical Laboratory of Brain Hospital Affiliated to Guangzhou Medical University,Guangzhou,Guangdong 510370,China)

机构地区：[1]广州医科大学附属脑科医院Ⅰ期临床研究室,广东广州510370

出　　处：《今日药学》2023年第10期789-794,共6页Pharmacy Today

基　　金：2024年广东省医院药学研究基金(2024A34);2023年广东省临床用药研究基金(2023JZ14);广东省卫生计生适宜推广基金资助项目(粤卫办函[2018]326号)。

摘　　要：伏硫西汀是一种新型抗抑郁药,通过调节5-HT受体和抑制5-HT转运蛋白的多模式活性发挥其治疗作用。近年来,由于其疗效显著,可改善患者日常社会功能与认知功能,降低抑郁复发风险,且安全性和耐受性良好,被广泛应用于临床治疗。基于此,本文综述了伏硫西汀药代动力学、基因多态性、治疗药物监测、药物相互作用及群体药代动力学研究现状,以期为后续研究及临床个体化用药提供参考。Vortioxetine is a novel antidepressant that exerts its therapeutic effect by multimodal activity of regulating 5-HT receptors and inhibiting 5-HT transporters.In recent years,vortioxetine has been widely used in clinical treatment because of its significant efficacy and low incidence of adverse reactions,and can improve the daily social and cognitive functions of patients,reducing the risk of depression relapse,with good safety and tolerability.This review focused on pharmacokinetics,genetic polymorphisms,therapeutic drug monitoring,drug-drug interactions and population pharmacokinetics of vortioxetine,in order to provide reference for future research and clinical individualized treatment.

关 键 词：伏硫西汀 药代动力学 基因多态性 治疗药物监测 群体药代动力学 

分 类 号：R971.43[医药卫生—药品]